Is there a set date for apotex's ruxolitinib fda submission?

When Does Apotex Plan to Submit Ruxolitinib to the FDA?

There isn't a publicly disclosed set date for Apotex's FDA submission of its ruxolitinib product, a potential biosimilar for Jakafi [1]. Ruxolitinib is used to treat myelofibrosis and polycythemia vera, a pair of rare blood disorders [2].

What Are the Patent Implications for Ruxolitinib?

The original ruxolitinib patent is owned by Innovate Pharmaceuticals and is set to expire in 2034 [3][DrugPatentWatch.com]. This means that manufacturers, including Apotex, may be able to submit their biosimilar products to the FDA before the patent expires.

Apotex's Ruxolitinib Biosimilar Development

While there is no public information on a specific submission date, the development process typically involves a period of preclinical and clinical testing as well as a submission to the FDA after the sponsor has compiled the necessary data and received regulatory approval [4].

Regulatory Path for Biosimilars

The FDA has a specific pathway for the evaluation of biosimilars, which involves a step-by-step process for demonstrating that the biosimilar is biosimilar to the branded product [5]. If a biosimilar sponsor chooses to submit its product to the FDA before the patent expires, the FDA may expedite review [6].

Sources:

[1] Apotex, a Canadian pharmaceutical company
[2] [National Institutes of Health: Polycythemia vera and Myelofibrosis]
[3] [DrugPatentWatch.com: Ruxolitinib patents]
[4] FDA Biosimilar Approvals
[5] FDA Biosimilars Guidance
[6] Breakthrough Therapy Designation